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AML incidence increases with age. Allo-SCT offers the best leuke-
mic control but is associated with high non-relapse mortality (NRM).
Recent advances using non-myeloablative strategies have established
the feasibility of allo-SCT in elderly patients (pts). However, in the
context of AML, a much too important reduction of preparative
regimen might be associated with a loss of leukemic control offsetting
the impact of toxicity reduction in elderly.To get some clues on this
subject, we retrospectively analyzed CR1 AML pts reported to the
SFGM-TC, aged above 55 and transplanted from a HLA identical
sibling prior to 01/01/05. Sixgty-two pts prepared with a non-myeloa-
blative conditioning (NMAC) (Fludarabine [75mg/m2]TBI [2Gy])
(n  14) or a reduced intensity conditioning (RIC) (busulfan [4 to 8
mg/m2]  ﬂudarabine [150 to 180 mg/m2]  thymoglobulin [2.5 to
12.5 mg/m2]) (n  48). GVHD prophylaxis used CSA  MMF for
NMAC, CSA / MMF for RIC. With few exceptions, all pts in a
given center were treated identically. Major characteristics: age 58
(55–67), M/F  27/35, time diagnosis-SCT: 171 days (101–467),
BMT/PBSCT: 7/55. Pts have been considered for allo-SCT for
presenting poor prognosis factors: no favorable cytogenetics (100%),
secondary leukemia (15%), 2 chemotherapy course to achieve CR1
(24%), or M0, M6, or M7 FAB (20%). All pts engrafted. AGVHD
occurred in 16 pts (grade 1: 6; grade 2: 6; grade 3–4: 4), and cGVHD
in 18 pts (limited: 8; extensive: 10) with no difference in the 2 groups.
The cumulative incidences of grade 2–4 aGVHD and cGVHD were
16% (95%CI: 7–25) and 29% (95%CI: 18–40), respectively. Fifteen
pts relapsed and 8 died from NRM. Relapse and NRM cumulative
incidences were 24% (95%CI: 13–35) and 13% (95% CI: 5–21),
respectively. Forty-nine pts were evaluable for cGVHD: of the 18
expressing cGVHDnone have relapsed compared to 12 of the 31 who
did not present cGVHD (39%, 95%CI: 22–56) ( P .007). Two year
KM survival and DFS probabilities are 63% (47–76) and 56% (42–
69). In a landmark analysis investigating pts alive on day 100, 2 year
DFS are 94% and 38%, respectively, with or without cGVHD (P 
.001) and 2 year KM OS are 94% and 45%, respectively, (P  .01).
We conclude that such a strategy in elderly can afford a high relapse
control with low NRM conducting to high survival probability at 2
years. Results are achieved through the allogeneic effect as expressed
by cGVHD inviting to a careful immunomodulation in the early post
transplant period to further improve results.
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Extramedullary (EM) relapse of leukemia after allogeneic stem
cell transplantation (allo-SCT) is increasingly reported. However,
its diagnosis is often delayed due to the diversity of the involved
sites and the lack of monitoring methods. In the present study, we
investigated the role of monitoring of the WT1 gene expression in
the early diagnosis with EM relapse. Methods: Between January
1998 and December 2003, 97 patients with AML (n  42), ALL
(n  22), CML (n  23), or MDS (n  10) underwent allo-SCT
at Osaka University Hospital. We retrospectively monitored the
WT1 gene expression level in the patients who had a bone marrow
(BM) or EM relapse after allo-SCT. Quantiﬁcation of the WT1
gene expression in BM and peripheral blood (PB) samples was
serially performed using real-time PCR. Results: Twenty-two out
of 97 patients who underwent allogeneic SCT had a relapse. Three
patterns of leukemia relapse were observed; BM relapse (17 pa-
tients), isolated EMR (4 patients), and EMR with BM relapse (1
patient). Among them, in 12 patients with BM relapse and 3
patients with isolated EMR, the WT1 expression levels in the BM
and PB could be concurrently monitored after transplantation. In
all the patients having a BM relapse, the WT1 expression levels in
the BM were greater than 1.0  102, and all these values were
higher than those in the PB. In contrast, in all 3 patients having an
EMR, the WT1 expression levels in the PB were abnormally high
(	1.0  103), and were higher than those in the BM even 11 to
46 days before the diagnosis. The BM/PB ratio of the WT1 gene
expression at the time of diagnosis of relapse was signiﬁcantly
lower in the patients with isolated EMR when compared with the
patients with BM relapse (P  .01). Conclusions: We demon-
strated, for the ﬁrst time, that an abnormally high WT1 expression
level in PB, which was greater than that in BM, was observed
exclusively in the patients with isolated EM relapse. Thus, a con-
current monitoring of MRD in BM and PB must be useful for early
diagnosis of EM relapse.
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Patients with Ph acute lymphoblastic leukemia (ALL) or
chronic myelogenous leukemia (CML) in stages other than ﬁrst
chronic phase (CP1) frequently have recurrent malignancy after
allogeneic hematopoietic cell transplant (HCT). Hypothesis: We
postulated that imatinib might be most effective for preventing
hematological relapse after myeloablative HCT if given immedi-
ately after engraftment to patients without detectable leukemia, or
with leukemia that can be detected only at the molecular level.
Study Design: A pilot study to evaluate the safety and preliminary
efﬁcacy of imatinib given early after engraftment until post-trans-
plant day 365 (D 365) nears complete accrual. Study participants
became eligible to start imatinib if the residual marrow leukemia
burden at the time of initial engraftment (ANC 	500 on 2 con-
secutive days) did not exceed 	1/20 Ph metaphases, 	1% aber-
rant antigen expression on blasts by multidimensional ﬂow, or
presence of bcr/abl in 	5% interphase nuclei by FISH. The
primary endpoint of safety was deﬁned by ability to tolerate ima-
tinib for 6 days/week until D  90. Patient Characteristics and
Results: (see Table below). All patients tolerated imatinib at the
intended dose intensity within the ﬁrst 90 days after HCT. Tox-
icities (NCI CTC v3.0) possibly attributed to imatinib included
grade 1–2 nausea (n 3), grade 1 edema (n 3), grade 1–2 anemia
(n 2), and grade 3 neutropenia (n 2). Per protocol, one patient
with neutropenia received 2 doses of G-CSF at D  75 and
continued imatinib without neutropenia. The second patient was
not given G-CSF and imatinib was held for 2 weeks from D  160
until the ANC was 	2000. All patients are alive at a median of 250
days after HCT (range, 27–627), and 17/18 patients have no
detectable bcr/abl transcripts in the blood or marrow. Seven pa-
tients ( ALL, 3 CML) have completed imatinib therapy and survive
at a median of 515 days after HCT (range, 416–627 days) and
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